Hypermarcas (OTCMKTS:HYPMY) Stock Breaks Below 200-Day Moving Average – What’s Next?

Posted by Francis Steltz on Oct 28th, 2026

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.44 and traded as low as $3.39. Hypermarcas shares last traded at $3.95, with a volume of 67,913 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

Check Out Our Latest Stock Analysis on Hypermarcas

Hypermarcas Price Performance

The firm has a 50 day simple moving average of $4.66 and a two-hundred day simple moving average of $4.44. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of 8.02 and a beta of 0.65.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, sell-side analysts expect that Hypermarcas will post 0.51 EPS for the current year.

About Hypermarcas

(Get Free Report)

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.